chlorambucil has been researched along with Recrudescence in 97 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Short-term chlorambucil therapy for refractory uveitis in Behcet's disease is effective in controlling the disease in two-thirds of patients." | 9.09 | Short-term chlorambucil for refractory uveitis in Behcet's disease. ( Arslan, MO; Burumcek, EY; Durlu, Y; Ergen, A; Ipcioglu, SU; Mudun, BA, 2001) |
| "Chlorambucil, in combination with prednisone, was compared with prednisone alone in a randomized controlled trial in 21 children with either steroid-dependent or frequently relapsing nephrotic syndrome to assess its effect on the duration of remission and the rate of relapse." | 9.04 | Chlorambucil treatment of frequently relapsing nephrotic syndrome. ( Grupe, WE; Ingelfinger, JR; Makker, SP, 1976) |
| "A controlled clinical trial was performed using two dosage regimens of chlorambucil to treat children with frequently relapsing nephrotic syndrome." | 9.04 | Chlorambucil dosage in frequently relapsing nephrotic syndrome: a controlled clinical trial. ( Baluarte, HJ; Gruskin, AB; Hiner, L, 1978) |
| "Twenty-six patients with bullous pemphigoid were treated with a combination of chlorambucil and a systemic corticosteroid; 23 completed treatment." | 7.68 | The use of chlorambucil in the treatment of bullous pemphigoid. ( Hutchinson, PE; Milligan, A, 1990) |
| "Mechlorethamine has been assessed in 28 patients with idiopathic nephrotic syndrome previously treated with prednisone only." | 7.67 | [Effect of mechlorethamine in idiopathic nephrotic syndrome in childhood]. ( Canals, MJ; Cervera, A; Gómez Campderá, FJ; Gómez Campderá, J; López Gómez, JM; Luque, A; Morales, JL, 1984) |
| " The heavy proteinuria exhibited a striking steroid-dependent course during a three-year period of time, with ten relapses occurring whenever attempts were made to withdraw prednisone therapy." | 7.67 | Steroid-dependent nephrotic syndrome in lupus nephritis. Response to chlorambucil. ( Abuelo, JG; Esparza, AR; Garella, S, 1984) |
| "A patient with an unusual variant of Sweet's syndrome, in which the course of the disease was chronic and relapsing, was treated successfully with intravenous methylprednisolone (pulse therapy)." | 7.67 | The use of pulse methylprednisolone and chlorambucil in the treatment of Sweet's syndrome. ( Callen, JP; Case, JD; Smith, SZ, 1989) |
| "Five patients with a steroid-responsive, frequently relapsing nephrotic syndrome who had failed at least one course of treatment with cyclophosphamide were all put into a long term remission with chlorambucil." | 7.67 | Remission induced by chlorambucil in steroid-responsive, frequently relapsing nephrotic syndrome that relapsed after cyclophosphamide. ( Bailey, RR, 1989) |
| "Short-term chlorambucil therapy for refractory uveitis in Behcet's disease is effective in controlling the disease in two-thirds of patients." | 5.09 | Short-term chlorambucil for refractory uveitis in Behcet's disease. ( Arslan, MO; Burumcek, EY; Durlu, Y; Ergen, A; Ipcioglu, SU; Mudun, BA, 2001) |
| "In order to elucidate long-term effects of immunosuppressants, we studied 60 children with steroid-dependent nephrotic syndrome who were treated with three immunosuppressants: cyclophosphamide (n=34), chlorambucil (n=11), and cyclosporin A (n=15)." | 5.08 | Long-term effects of immunosuppressants in steroid-dependent nephrotic syndrome. ( Matsutani, H; Niimura, F; Ohgushi, H; Takeda, A, 1998) |
| "Chlorambucil, in combination with prednisone, was compared with prednisone alone in a randomized controlled trial in 21 children with either steroid-dependent or frequently relapsing nephrotic syndrome to assess its effect on the duration of remission and the rate of relapse." | 5.04 | Chlorambucil treatment of frequently relapsing nephrotic syndrome. ( Grupe, WE; Ingelfinger, JR; Makker, SP, 1976) |
| "A controlled clinical trial was performed using two dosage regimens of chlorambucil to treat children with frequently relapsing nephrotic syndrome." | 5.04 | Chlorambucil dosage in frequently relapsing nephrotic syndrome: a controlled clinical trial. ( Baluarte, HJ; Gruskin, AB; Hiner, L, 1978) |
| "Hairy cell leukemia (HCL) is characterized by leukemic cells with abundant "hairy" cytoplasm, strong cytoplasmic positivity for tartrate-resistant acid phosphatase (TRAP), characteristic immunophenotype and sensitivity to treatment with purine nucleoside analogs." | 4.87 | Hairy cell leukemia and variant in Taiwan: report of a variant case and literature review. ( Chang, ST; Chuang, SS; Hsieh, YC; Li, CY; Lin, CN; Lu, CL; Tsao, CJ, 2011) |
| "For over 30 years cyclophosphamide (CYC) and chlorambucil (CHL) have been used to treat children with relapsing steroid-sensitive nephrotic syndrome (SSNS)." | 4.81 | A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. ( Ehrich, JH; Latta, K; von Schnakenburg, C, 2001) |
| "Intensive and prolonged systemic treatment with corticosteroids is recommended for the patients with first attack of VKH syndrome, where as regular treatment with chlorambucil is useful for control of chronic and recurrent uveitis seen in VKH syndrome." | 3.71 | [Therapeutic regimen in Vogt-Koyanagi-Harada syndrome]. ( Fu, T; Huang, X; Li, F; Wang, H; Yang, P; Zhong, H; Zhou, H, 2002) |
| " malariae infection that acutely reactivated after 45 y of latency following treatment with chlorambucil and methylprednisolone is reported." | 3.70 | Drug-induced acute malaria. ( Bassaris, H; Skoutelis, A; Symeonidis, A; Vassalou, E, 2000) |
| "Twenty-six patients with bullous pemphigoid were treated with a combination of chlorambucil and a systemic corticosteroid; 23 completed treatment." | 3.68 | The use of chlorambucil in the treatment of bullous pemphigoid. ( Hutchinson, PE; Milligan, A, 1990) |
| "We administered Bestrabucil, a benzoate ester of a complex of beta-estradiol and chlorambucil, continuously to six patients with breast cancer recurrent to local and regional lymph nodes, at a dose level of 200 mg/day." | 3.67 | [Therapeutic results in recurrent breast cancer with the use of Bestrabucil (KM2210)]. ( Morimoto, K; Nakatani, S; Sakai, K; Ueda, T, 1987) |
| "Mechlorethamine has been assessed in 28 patients with idiopathic nephrotic syndrome previously treated with prednisone only." | 3.67 | [Effect of mechlorethamine in idiopathic nephrotic syndrome in childhood]. ( Canals, MJ; Cervera, A; Gómez Campderá, FJ; Gómez Campderá, J; López Gómez, JM; Luque, A; Morales, JL, 1984) |
| " The heavy proteinuria exhibited a striking steroid-dependent course during a three-year period of time, with ten relapses occurring whenever attempts were made to withdraw prednisone therapy." | 3.67 | Steroid-dependent nephrotic syndrome in lupus nephritis. Response to chlorambucil. ( Abuelo, JG; Esparza, AR; Garella, S, 1984) |
| "A patient with an unusual variant of Sweet's syndrome, in which the course of the disease was chronic and relapsing, was treated successfully with intravenous methylprednisolone (pulse therapy)." | 3.67 | The use of pulse methylprednisolone and chlorambucil in the treatment of Sweet's syndrome. ( Callen, JP; Case, JD; Smith, SZ, 1989) |
| "Growth velocity measurements were assessed in 12 children with steroid responsive but frequent relapsing or dependent nephrotic syndrome prior to and following treatment with either cyclophosphamide or chlorambucil and alternate day prednisone." | 3.67 | Linear growth of children with nephrotic syndrome: effect of alkylating agents. ( Brem, AS; Padilla, R, 1989) |
| "Five patients with a steroid-responsive, frequently relapsing nephrotic syndrome who had failed at least one course of treatment with cyclophosphamide were all put into a long term remission with chlorambucil." | 3.67 | Remission induced by chlorambucil in steroid-responsive, frequently relapsing nephrotic syndrome that relapsed after cyclophosphamide. ( Bailey, RR, 1989) |
| "Achievement of minimal residual disease negativity was greatest in 1L patients treated with G-FC." | 3.01 | Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. ( Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M, 2021) |
| "Patients with biopsy-proven membranous nephropathy and with a nephrotic syndrome were randomized to be given methylprednisolone (1 g intravenously for 3 consecutive days followed by oral methylprednisolone, 0." | 2.69 | A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. ( Altieri, P; Antonucci, F; Bellazzi, R; Cesana, B; Dugo, M; Farina, M; Grassi, C; Lupo, A; Melis, P; Minari, M; Pasquali, S; Passerini, P; Pedrini, L; Piccoli, G; Pisano, G; Ponticelli, C; Pozzi, C; Roccatello, D; Sasdelli, M; Scalia, A; Scolari, F; Segagni, S; Valzorio, B, 1998) |
| "The natural course of idiopathic membranous nephropathy is variable, with some patients slowly progressing to renal failure while others maintain normal renal function over the entire time." | 2.68 | A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. ( Cesana, B; Grassi, C; Locatelli, F; Pasquali, S; Passerini, P; Ponticelli, C; Pozzi, C; Redaelli, B; Sasdelli, M; Zucchelli, P, 1995) |
| "Fewest relapses have been seen in patients who received IFN-alpha 2b throughout." | 2.67 | Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. ( Bailey, N; Blackledge, G; Crowther, D; Deakin, D; Lister, TA; Norton, A; Price, CG; Rohatiner, AZ; Steward, W, 1991) |
| " Long-term follow-up trials focused on gonadal toxicity and limitation of maximum dosage of cyclophosphamide should been carried out." | 2.61 | Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials. ( Li, Q; Li, S; Tan, L; Wan, J; Yang, H; Zou, Q, 2019) |
| "Proteinuria was negative one year before and no signs of diabetic retinopathy were found." | 1.32 | [Relapsing nephrotic syndrome in a diabetic patient with minimal change]. ( Espejo, B; García Donaire, JA; Gutiérrez Martínez, E; Manzanera, MI; Praga, M; Valentín, MO, 2004) |
| "Chlorambucil has been used for many years for the treatment of low-grade B-cell lymphoproliferative disorders, including chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma." | 1.31 | High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma. ( Mounter, PJ; Proctor, SJ; Summerfield, GP; Taylor, PR, 2002) |
| " Gender, age at onset, duration of illness from onset, prednisolone dosage at the most-recent relapse, and regimens of initial steroid therapy at onset were not associated with risk." | 1.31 | Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome. ( Mizusawa, Y; Simoda, M; Takeda, A; Takimoto, H, 2001) |
| "Levamisole was given to 56 children (13%) and cyclosporin to 53 (12%)." | 1.29 | Alternative treatment to corticosteroids in steroid sensitive idiopathic nephrotic syndrome. ( Barratt, TM; Dillon, MJ; Fay, J; Neuhaus, TJ; Trompeter, RS, 1994) |
| " When the glucocorticoid dosage was reduced or the drug discontinued, the nephrotic syndrome recurred." | 1.29 | [T-cell lymphoma under immunosuppressive treatment in minimal change glomerulopathy with nephrotic syndrome]. ( Schollmeyer, P; Späth, M, 1995) |
| "Fifteen patients with chronic lymphocytic leukemia (CLL) were treated in a phase I-II study of chlorambucil with an escalating dose of fludarabine." | 1.29 | Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. ( Berman, E; Kempin, S; Spiess, T; Weiss, M, 1994) |
| "B-cell chronic lymphocytic leukemia (CLL) initially responds well to treatment with alkylating agents, but subsequently resistance may develop." | 1.29 | Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance. ( Juliusson, G; Liliemark, J, 1994) |
| "Patients with Hodgkin's disease who were previously untreated with chemotherapy received the chlorambucil, vinblastine, procarbazine, and prednisone (CHLVPP) regimen plus limited involved-field radiation therapy for treatment of Hodgkin's disease through the Nebraska Lymphoma Study Group." | 1.28 | CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicity. ( Anderson, JR; Bierman, PJ; Dowling, MD; Howe, D; Hutchins, M; Moravec, DF; Okerbloom, J; Sorensen, S; Vose, JM; Weisenburger, D, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (45.36) | 18.7374 |
| 1990's | 21 (21.65) | 18.2507 |
| 2000's | 22 (22.68) | 29.6817 |
| 2010's | 8 (8.25) | 24.3611 |
| 2020's | 2 (2.06) | 2.80 |
| Authors | Studies |
|---|---|
| Larkins, NG | 1 |
| Liu, ID | 1 |
| Willis, NS | 2 |
| Craig, JC | 2 |
| Hodson, EM | 2 |
| Stilgenbauer, S | 1 |
| Bosch, F | 1 |
| Ilhan, O | 1 |
| Kisro, J | 1 |
| Mahé, B | 1 |
| Mikuskova, E | 1 |
| Osmanov, D | 1 |
| Reda, G | 1 |
| Robinson, S | 1 |
| Tausch, E | 1 |
| Turgut, M | 1 |
| Wójtowicz, M | 1 |
| Böttcher, S | 1 |
| Perretti, T | 1 |
| Trask, P | 1 |
| Van Hoef, M | 1 |
| Leblond, V | 1 |
| Foà, R | 1 |
| Tan, L | 1 |
| Li, S | 1 |
| Yang, H | 1 |
| Zou, Q | 1 |
| Wan, J | 1 |
| Li, Q | 1 |
| Ruiz-Medrano, J | 1 |
| Peralta-Díaz, LM | 1 |
| Santos-Bueso, E | 1 |
| Shankar, A | 2 |
| Hayward, J | 1 |
| Kirkwood, A | 1 |
| McCarthy, K | 2 |
| Hewitt, M | 2 |
| Morland, B | 1 |
| Daw, S | 2 |
| Bhagat, P | 1 |
| Sachdeva, MU | 1 |
| Sharma, P | 1 |
| Naseem, S | 1 |
| Ahluwalia, J | 1 |
| Das, R | 1 |
| Varma, N | 1 |
| Law, A | 1 |
| Malhotra, P | 1 |
| Zhao, XL | 1 |
| Wei, SN | 1 |
| Liu, KQ | 1 |
| Lin, D | 1 |
| Wei, H | 1 |
| Wang, Y | 1 |
| Zhou, CL | 1 |
| Liu, BC | 1 |
| Li, W | 1 |
| Cao, Z | 1 |
| Gong, BF | 1 |
| Liu, YT | 1 |
| Gong, XY | 1 |
| Li, Y | 1 |
| Gu, RX | 1 |
| Zhang, GJ | 1 |
| Wang, JX | 1 |
| Mi, YC | 1 |
| Antoniou, C | 1 |
| Stefanaki, C | 1 |
| Ioannidou, D | 1 |
| Tasidou, A | 1 |
| Pigaditou, A | 1 |
| Katsambas, A | 1 |
| Kniazewska, MH | 1 |
| Obuchowicz, AK | 1 |
| Wielkoszyński, T | 1 |
| Zmudzińska-Kitczak, J | 1 |
| Urban, K | 1 |
| Hyla-Klekot, L | 1 |
| Perez, K | 1 |
| Winer, ES | 1 |
| Hsieh, YC | 1 |
| Chang, ST | 1 |
| Chuang, SS | 1 |
| Lu, CL | 1 |
| Tsao, CJ | 1 |
| Lin, CN | 1 |
| Li, CY | 1 |
| Pentsova, E | 1 |
| Rosenblum, M | 1 |
| Holodny, A | 1 |
| Palomba, ML | 1 |
| Omuro, A | 1 |
| Yang, P | 1 |
| Wang, H | 1 |
| Zhou, H | 1 |
| Zhong, H | 2 |
| Li, F | 1 |
| Huang, X | 1 |
| Fu, T | 1 |
| Kolyvanos Naumann, U | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| García Donaire, JA | 1 |
| Manzanera, MI | 1 |
| Valentín, MO | 1 |
| Espejo, B | 1 |
| Gutiérrez Martínez, E | 1 |
| Praga, M | 2 |
| Robinson, H | 1 |
| Rymes, N | 1 |
| Rüth, EM | 1 |
| Kemper, MJ | 1 |
| Leumann, EP | 1 |
| Laube, GF | 1 |
| Neuhaus, TJ | 2 |
| Willis, CR | 1 |
| Goodrich, A | 1 |
| Park, K | 1 |
| Waselenko, JK | 1 |
| Lucas, M | 1 |
| Reese, A | 1 |
| Diehl, LF | 1 |
| Grever, MR | 1 |
| Byrd, JC | 1 |
| Flinn, IW | 1 |
| Marcus, R | 1 |
| Hattori, M | 1 |
| Hall, GW | 1 |
| Katzilakis, N | 1 |
| Pinkerton, CR | 1 |
| Nicolin, G | 1 |
| Ashley, S | 1 |
| Wallace, WH | 1 |
| Sureda, NC | 1 |
| Bosch, MP | 1 |
| Kurpis, M | 1 |
| Ruiz Lascano, A | 1 |
| Schärer, K | 1 |
| Gómez Campderá, FJ | 1 |
| López Gómez, JM | 1 |
| Cervera, A | 1 |
| Gómez Campderá, J | 1 |
| Canals, MJ | 1 |
| Morales, JL | 1 |
| Luque, A | 1 |
| Abuelo, JG | 1 |
| Esparza, AR | 1 |
| Garella, S | 1 |
| Tanphaichitr, P | 1 |
| Tanphaichitr, D | 1 |
| Sureeratanan, J | 1 |
| Chatasingh, S | 1 |
| Kleinknecht, C | 1 |
| Broyer, M | 1 |
| Jarde, O | 1 |
| Guillot, M | 1 |
| McEnery, PT | 1 |
| Strife, CF | 1 |
| Allen, WR | 1 |
| Travis, LB | 1 |
| Cavallo, T | 1 |
| Brouhard, BH | 1 |
| Cunningham, RJ | 1 |
| Davis, JH | 1 |
| Lewis, EJ | 1 |
| Herin, P | 1 |
| Eriksson, M | 1 |
| Späth, M | 1 |
| Schollmeyer, P | 1 |
| Fay, J | 1 |
| Dillon, MJ | 1 |
| Trompeter, RS | 1 |
| Barratt, TM | 1 |
| Juliusson, G | 1 |
| Liliemark, J | 1 |
| Weiss, M | 1 |
| Spiess, T | 1 |
| Berman, E | 1 |
| Kempin, S | 1 |
| Brodehl, J | 4 |
| Haak, HL | 1 |
| Gerrits, WB | 1 |
| Wijermans, PW | 1 |
| Kerkhofs, H | 1 |
| Joseph, G | 1 |
| Hadley, T | 1 |
| Djulbegovic, B | 1 |
| Hamm, J | 1 |
| Seeger, J | 1 |
| Blumenreich, M | 1 |
| Woodcock, T | 1 |
| Ponticelli, C | 2 |
| Zucchelli, P | 1 |
| Passerini, P | 2 |
| Cesana, B | 2 |
| Locatelli, F | 1 |
| Pasquali, S | 2 |
| Sasdelli, M | 2 |
| Redaelli, B | 1 |
| Grassi, C | 2 |
| Pozzi, C | 2 |
| Avilés, A | 1 |
| Talavera, A | 1 |
| Guzmán, R | 1 |
| Cuadra, I | 1 |
| Denham, JW | 1 |
| Denham, E | 1 |
| Dear, KB | 1 |
| Hudson, GV | 1 |
| Altieri, P | 1 |
| Scolari, F | 1 |
| Roccatello, D | 1 |
| Melis, P | 1 |
| Valzorio, B | 1 |
| Piccoli, G | 1 |
| Lupo, A | 1 |
| Segagni, S | 1 |
| Antonucci, F | 1 |
| Dugo, M | 1 |
| Minari, M | 1 |
| Scalia, A | 1 |
| Pedrini, L | 1 |
| Pisano, G | 1 |
| Farina, M | 1 |
| Bellazzi, R | 1 |
| Whallett, AJ | 1 |
| Gillott, TJ | 1 |
| Klocke, R | 1 |
| Coppock, JS | 1 |
| Takeda, A | 2 |
| Ohgushi, H | 1 |
| Niimura, F | 1 |
| Matsutani, H | 1 |
| Carreño, A | 1 |
| Morales, E | 1 |
| Domínguez-Gil, B | 1 |
| Herrero, JC | 1 |
| Ortiz, M | 1 |
| González, E | 1 |
| Skoutelis, A | 1 |
| Symeonidis, A | 1 |
| Vassalou, E | 1 |
| Bassaris, H | 1 |
| Kaklamani, VG | 1 |
| Kaklamanis, PG | 1 |
| Durkan, AM | 1 |
| Latta, K | 1 |
| von Schnakenburg, C | 1 |
| Ehrich, JH | 1 |
| Robak, T | 1 |
| Błoński , JZ | 1 |
| Kasznicki, M | 1 |
| Takimoto, H | 1 |
| Mizusawa, Y | 1 |
| Simoda, M | 1 |
| Durkan, A | 1 |
| Hodson, E | 1 |
| Willis, N | 1 |
| Craig, J | 1 |
| Summerfield, GP | 1 |
| Taylor, PR | 1 |
| Mounter, PJ | 1 |
| Proctor, SJ | 1 |
| Mudun, BA | 1 |
| Ergen, A | 1 |
| Ipcioglu, SU | 1 |
| Burumcek, EY | 1 |
| Durlu, Y | 1 |
| Arslan, MO | 1 |
| Alatas, H | 1 |
| Wirya, IG | 1 |
| Tambunan, T | 1 |
| Himawan, S | 1 |
| Sitnitskaia, IG | 1 |
| Bagdasarova, IV | 1 |
| Panchenko, VI | 1 |
| Senn, HJ | 2 |
| Jungi, WF | 1 |
| Amgwerd, R | 1 |
| Sprenger, F | 1 |
| Hochuli, E | 1 |
| Engelhart, G | 1 |
| Heinz, C | 1 |
| Wick, A | 1 |
| Enderlin, F | 1 |
| Simeon, B | 1 |
| Lanz, R | 1 |
| Bigler, R | 1 |
| Mayr, AC | 1 |
| Vázquez Tadei, G | 1 |
| Fernández, J | 1 |
| Martin Malo, A | 1 |
| Campdera, FG | 1 |
| Sanz Guajardo, D | 1 |
| Traver, JA | 1 |
| Botella, J | 1 |
| Stout, R | 1 |
| Todd, ID | 1 |
| Baluarte, HJ | 1 |
| Hiner, L | 1 |
| Gruskin, AB | 1 |
| MacDougall, BK | 1 |
| Weinerman, BH | 1 |
| Renier, JC | 1 |
| Bregeon, C | 1 |
| Bonnette, C | 1 |
| Brandis, M | 1 |
| Krohn, HP | 1 |
| Hanke, K | 1 |
| Grupe, WE | 2 |
| Makker, SP | 2 |
| Ingelfinger, JR | 1 |
| Mamo, JG | 1 |
| Niaudet, P | 2 |
| Price, CG | 1 |
| Rohatiner, AZ | 1 |
| Steward, W | 1 |
| Deakin, D | 1 |
| Bailey, N | 1 |
| Norton, A | 1 |
| Blackledge, G | 1 |
| Crowther, D | 1 |
| Lister, TA | 1 |
| Vose, JM | 1 |
| Bierman, PJ | 1 |
| Anderson, JR | 1 |
| Weisenburger, D | 1 |
| Moravec, DF | 1 |
| Sorensen, S | 1 |
| Hutchins, M | 1 |
| Dowling, MD | 1 |
| Howe, D | 1 |
| Okerbloom, J | 1 |
| Milligan, A | 1 |
| Hutchinson, PE | 1 |
| Glynne-Jones, R | 1 |
| Whitaker, SJ | 1 |
| Plowman, PN | 1 |
| Case, JD | 1 |
| Smith, SZ | 1 |
| Callen, JP | 1 |
| Padilla, R | 1 |
| Brem, AS | 1 |
| Bailey, RR | 1 |
| Druker, BJ | 1 |
| Rosenthal, DS | 1 |
| Canellos, GP | 1 |
| Bernengo, MG | 1 |
| Meregalli, M | 1 |
| Jemma, C | 1 |
| Lisa, F | 1 |
| Tejani, A | 1 |
| Jones, DP | 1 |
| Stapleton, FB | 1 |
| Roy, S | 1 |
| Wyatt, RJ | 1 |
| Ueda, T | 1 |
| Sakai, K | 1 |
| Morimoto, K | 1 |
| Nakatani, S | 1 |
| Shapiro, CM | 1 |
| Vander Laan, BF | 1 |
| Jao, W | 1 |
| Sloan, DE | 1 |
| Kampf, D | 1 |
| Baethke, R | 1 |
| McLaren, JH | 1 |
| Papac, RJ | 1 |
| Hooft, C | 1 |
| van Acker, KJ | 1 |
| Godfrey, WA | 1 |
| Epstein, WV | 1 |
| O'Connor, GR | 1 |
| Kimura, SJ | 1 |
| Hogan, MJ | 1 |
| Nozik, RA | 1 |
| Schmidt, CG | 1 |
| Mukherji, B | 1 |
| Yagoda, A | 1 |
| Lee, BJ | 1 |
| Krakoff, IH | 1 |
| Nisce, LZ | 1 |
| Geller, W | 1 |
| D'Angio, GJ | 1 |
| Heymann, W | 1 |
| Chiu, J | 1 |
| Drummond, KN | 1 |
| Cameron, JS | 1 |
| Borin, IaV | 1 |
| Rapoport, GL | 1 |
| Iurkevich, ST | 1 |
| Bondarenko, MN | 1 |
| Stögmann, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia[NCT01905943] | Phase 3 | 979 participants (Actual) | Interventional | 2013-11-04 | Completed | ||
| Ofatumumab in Children With Steroid- and Calcineurin-inhibitor-resistant Nephrotic Syndrome: a Double-blind Randomized, Controlled, Superiority Trial[NCT02394106] | Phase 2 | 13 participants (Actual) | Interventional | 2015-07-31 | Terminated | ||
| Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor-dependent Idiopathic Nephrotic Syndrome: an Open-label, Randomized, Controlled, Superiority Trial.[NCT02394119] | Phase 2 | 140 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy[NCT03018535] | Phase 3 | 76 participants (Actual) | Interventional | 2012-01-31 | Active, not recruiting | ||
| Random, Open, Control and Monocentric Clinical Research on Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)[NCT03549663] | 108 participants (Anticipated) | Interventional | 2018-07-04 | Recruiting | |||
| Clinical Study of Rituximab or Cyclophosphamide Combined With Steroids in the Treatment of Idiopathic Membranous Nephropathy[NCT05514015] | Phase 4 | 72 participants (Anticipated) | Interventional | 2022-08-25 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Kaplan Meier estimate of median DoR was defined as the time at which half of the responding (PR or CR) participants had progressed (PD) or died from any cause, whichever occurred first. PR: >/= 50% decrease in peripheral blood lymphocyte count AND >/= 50% reduction in lymphadenopathy OR >/= 50% reduction of liver enlargement OR >/= 50% reduction of spleen PLUS one of the following: neutrophils >1,500/mcL, platelets > 100,000/mcL, hemoglobin > 110 g/L OR >/= 50% increase in neutrophils, platelets or hemoglobin. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils >1,500/mcL, platelets > 100,000/mcL, hemoglobin > 110 g/L and bone marrow normocellular for age. PD: as defined in the description for Event-Free Survival outcome measure. (NCT01905943)
Timeframe: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
| Intervention | months (Median) |
|---|---|
| G Mono: Previously Untreated Fit | 40.1 |
| G Mono: Previously Untreated Unfit | 20.1 |
| G Mono: Relapsed/Refractory | 15.0 |
| G-Benda: Previously Untreated Fit | 55.0 |
| G-Benda: Previously Untreated Unfit | 49.3 |
| G-Benda: Relapsed/Refractory | 25.5 |
| G-FC: Previously Untreated Fit | NA |
| G-FC: Previously Untreated Unfit | NA |
| G-FC: Relapsed/Refractory | 21.2 |
| G-Clb: Previously Untreated Fit | 28.1 |
| G-Clb: Previously Untreated Unfit | 28.1 |
| G-Clb: Relapsed/Refractory | 12.3 |
Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed as assessed by investigator based on IWCLL tumor response criteria, or have initiated a non-protocol-specified anti-leukemia therapy or died, whichever occurs first. PD: at least 1 of the following: >/= 50% increase in absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, >/= 50% increase in longest diameter of any previous site of clinically significant lymphadenopathy, >/= 50% increase in enlargement of liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL. (NCT01905943)
Timeframe: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
| Intervention | months (Median) |
|---|---|
| G Mono: Previously Untreated Fit | 35.2 |
| G Mono: Previously Untreated Unfit | 17.9 |
| G Mono: Relapsed/Refractory | 14.0 |
| G-Benda: Previously Untreated Fit | 58.0 |
| G-Benda: Previously Untreated Unfit | 52.9 |
| G-Benda: Relapsed/Refractory | 25.1 |
| G-FC: Previously Untreated Fit | NA |
| G-FC: Previously Untreated Unfit | NA |
| G-FC: Relapsed/Refractory | 24.2 |
| G-Clb: Previously Untreated Fit | 31.3 |
| G-Clb: Previously Untreated Unfit | 31.8 |
| G-Clb: Relapsed/Refractory | 13.7 |
Kaplan Meier estimate of median TTNT was defined as the time at which half of the participants have initiated a new anti-leukemic therapy. (NCT01905943)
Timeframe: Baseline until end of study (up to approximately 5 years)
| Intervention | months (Median) |
|---|---|
| G Mono: Previously Untreated Fit | NA |
| G Mono: Previously Untreated Unfit | NA |
| G Mono: Relapsed/Refractory | 22.5 |
| G-Benda: Previously Untreated Fit | NA |
| G-Benda: Previously Untreated Unfit | NA |
| G-Benda: Relapsed/Refractory | 38.3 |
| G-FC: Previously Untreated Fit | NA |
| G-FC: Previously Untreated Unfit | NA |
| G-FC: Relapsed/Refractory | 32.6 |
| G-Clb: Previously Untreated Fit | NA |
| G-Clb: Previously Untreated Unfit | 53.7 |
| G-Clb: Relapsed/Refractory | 20.4 |
Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death. (NCT01905943)
Timeframe: Baseline until death (Approximately up to 5 years)
| Intervention | months (Median) |
|---|---|
| G Mono: Previously Untreated Fit | NA |
| G Mono: Previously Untreated Unfit | NA |
| G Mono: Relapsed/Refractory | NA |
| G-Benda: Previously Untreated Fit | NA |
| G-Benda: Previously Untreated Unfit | NA |
| G-Benda: Relapsed/Refractory | NA |
| G-FC: Previously Untreated Fit | NA |
| G-FC: Previously Untreated Unfit | NA |
| G-FC: Relapsed/Refractory | NA |
| G-Clb: Previously Untreated Fit | NA |
| G-Clb: Previously Untreated Unfit | NA |
| G-Clb: Relapsed/Refractory | NA |
Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease [PD]) based on IWCLL tumor response criteria or died from any cause, whichever occurred first. PD: at least one of the following: >/= 50% increase in the absolute number of circulating lymphocytes to at least 5,000/mcL, appearance of new palpable lymph nodes, >/= 50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, >/= 50% increase in the enlargement of the liver and/or spleen, transformation to more aggressive histology, progression of any cytopenia, decrease of hemoglobin levels by more than 20 g/L or to less than 100 g/L, decrease of platelet counts by more than 50% or to less than 100,000 /mcL, decrease of neutrophil counts by more than 50% or to less than 1,000/mcL. (NCT01905943)
Timeframe: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
| Intervention | months (Median) |
|---|---|
| G Mono: Previously Untreated Fit | 43.0 |
| G Mono: Previously Untreated Unfit | 21.2 |
| G Mono: Relapsed/Refractory | 17.6 |
| G-Benda: Previously Untreated Fit | 58.0 |
| G-Benda: Previously Untreated Unfit | NA |
| G-Benda: Relapsed/Refractory | 28.6 |
| G-FC: Previously Untreated Fit | NA |
| G-FC: Previously Untreated Unfit | NA |
| G-FC: Relapsed/Refractory | 24.8 |
| G-Clb: Previously Untreated Fit | 31.3 |
| G-Clb: Previously Untreated Unfit | 31.8 |
| G-Clb: Relapsed/Refractory | 14.1 |
Kaplan Meier estimate of median TTR was defined as the time at which half of the participants reached CR or PR based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils >1,500/mcL, platelets > 100,000/mcL, hemoglobin > 110 g/L and bone marrow normocellular for age. PR: >/= 50% decrease in peripheral blood lymphocyte count AND >/= 50% reduction in lymphadenopathy OR >/= 50% reduction of liver enlargement OR >/= 50% reduction of spleen PLUS one of the following: neutrophils >1,500/mcL, platelets > 100,000/mcL, hemoglobin > 110 g/L OR >/= 50% increase in neutrophils, platelets or hemoglobin. (NCT01905943)
Timeframe: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
| Intervention | months (Median) |
|---|---|
| G Mono: Previously Untreated Fit | 3.6 |
| G Mono: Previously Untreated Unfit | 3.6 |
| G Mono: Relapsed/Refractory | 3.9 |
| G-Benda: Previously Untreated Fit | 3.5 |
| G-Benda: Previously Untreated Unfit | 3.5 |
| G-Benda: Relapsed/Refractory | 3.7 |
| G-FC: Previously Untreated Fit | 3.6 |
| G-FC: Previously Untreated Unfit | 4.1 |
| G-FC: Relapsed/Refractory | 3.6 |
| G-Clb: Previously Untreated Fit | 3.3 |
| G-Clb: Previously Untreated Unfit | 3.6 |
| G-Clb: Relapsed/Refractory | 3.7 |
BOR was defined as the percentage of participants with the best response obtained throughout the trial with CR, CRi, or PR, as determined by the investigator based on IWCLL tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils >1,500/mcL, platelets > 100,000/mcL, hemoglobin > 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: >/= 50% decrease in peripheral blood lymphocyte count AND >/= 50% reduction in lymphadenopathy OR >/= 50% reduction of liver enlargement OR >/= 50% reduction of spleen PLUS one of the following: neutrophils >1,500/mcL, platelets > 100,000/mcL, hemoglobin > 110 g/L OR >/= 50% increase in neutrophils, platelets or hemoglobin. (NCT01905943)
Timeframe: Baseline, Day 85, end of treatment or early termination, and follow-up, assessed up to disease progression or death, whichever occurs first (up to approximately 5 years)
| Intervention | percentage of participants (Number) |
|---|---|
| G Mono: Previously Untreated Fit | 83.9 |
| G Mono: Previously Untreated Unfit | 71.9 |
| G Mono: Relapsed/Refractory | 60.0 |
| G-Benda: Previously Untreated Fit | 91.7 |
| G-Benda: Previously Untreated Unfit | 93.9 |
| G-Benda: Relapsed/Refractory | 86.8 |
| G-FC: Previously Untreated Fit | 97.1 |
| G-FC: Previously Untreated Unfit | 84.6 |
| G-FC: Relapsed/Refractory | 97.5 |
| G-Clb: Previously Untreated Fit | 100 |
| G-Clb: Previously Untreated Unfit | 94.0 |
| G-Clb: Relapsed/Refractory | 84.8 |
OR: percentage of participants with complete response (CR) or CR with incomplete marrow recovery (CRi), or partial response (PR), as determined by the investigator based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) tumor response criteria. CR: Peripheral blood lymphocytes 4,000/mcL, no significant lymphadenopathy, no hepatomegaly and splenomegaly, no disease symptoms, blood counts: neutrophils >1,500/mcL, platelets > 100,000/mcL, hemoglobin > 110 g/L and bone marrow normocellular for age. Cri: CR with persistent cytopenia. PR: >/= 50% decrease in peripheral blood lymphocyte count AND >/= 50% reduction in lymphadenopathy OR >/= 50% reduction of liver enlargement OR >/= 50% reduction of spleen PLUS one of the following: neutrophils >1,500/mcL, platelets > 100,000/mcL, hemoglobin > 110 g/L OR >/= 50% increase in neutrophils, platelets or hemoglobin. (NCT01905943)
Timeframe: 3 months after the last dose of study treatment (up to approximately 5 years)
| Intervention | percentage of participants (Number) |
|---|---|
| G Mono: Previously Untreated Fit | 71.0 |
| G Mono: Previously Untreated Unfit | 59.4 |
| G Mono: Relapsed/Refractory | 41.5 |
| G-Benda: Previously Untreated Fit | 83.9 |
| G-Benda: Previously Untreated Unfit | 81.6 |
| G-Benda: Relapsed/Refractory | 73.2 |
| G-FC: Previously Untreated Fit | 90.0 |
| G-FC: Previously Untreated Unfit | 84.6 |
| G-FC: Relapsed/Refractory | 85.0 |
| G-Clb: Previously Untreated Fit | 100 |
| G-Clb: Previously Untreated Unfit | 82.1 |
| G-Clb: Relapsed/Refractory | 56.5 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs, including AEs of Special Interest and AEs of Particular Interest, were reported based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0). Reported are the number of subjects with AEs, Grade 3-5 AEs, and Serious Adverse Events (SAEs). (NCT01905943)
Timeframe: Baseline up to time of primary completion (3 years)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| AEs | Grade 3-5 AEs | SAEs | |
| Obinutuzumab | 950 | 780 | 516 |
"The following AEs were defined as AEPIs: AEs with the preferred term Progressive multifocal leukoencephalopathy (PML), hepatitis B reactivation defined as AEs with preferred term containing Hepatitis B or hepatitis acute, thrombocytopenia defined via Roche MedDRA basket subgroup haematopoietic thrombocytopenia, second malignancies defined as AEs from the SOC Neoplasms benign, malignant and unspecified starting 6 months after the first study drug intake, second malignancies based on standardised MedDRA queries (SMQ) starting 6 months after the first study drug intake based on the MedDRA SMQ Malignant or unspecified tumours, in which benign neoplasms are not included, Cardiac events including AEs from the SOC Cardiac disorders, and hemorrhagic events defined via Roche MedDRA basket subgroup Haemorrhagic events. Reported are number of participants with total AEPIs and each of the AEPI categories." (NCT01905943)
Timeframe: Baseline up to time of primary completion (3 years)
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total AEPIs | Thrombocytopenia | Cardiac events | Second malignancies | Second malignancies (SMQ) | Hemorrhagic events | Hepatitis B reactivation | PML | |
| Obinutuzumab | 467 | 314 | 109 | 82 | 75 | 69 | 3 | 1 |
"The following AEs were defined as AESIs: AEs with the preferred term Tumour Lysis Syndrome (TLS), Infusion-Related Reactions (IRRs) defined as AEs that occurred during or within 24 hours of the completion of obinutuzumab infusion and were assessed as related to obinutuzumab by the Investigator, Infections defined as AEs from System Organ Class (SOC) Infections and infestations and AEs with the preferred term Neutropenia. Reported are number of participants with total AESIs, IRRs, Infections, Neutropenia and TLS." (NCT01905943)
Timeframe: Baseline up to time of primary completion (3 years)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Total AESIs | IRRs | Neutropenia | Infections | TLS | |
| Obinutuzumab | 905 | 635 | 599 | 521 | 62 |
MRD-negativity was defined as the presence of less than 1 chronic lymphocytic leukemia (CLL) cell per 10,000 leukocytes in blood and bone marrow as assessed by flow cytometry 3 months after last dose of study treatment (i.e. at final response assessment [FRA] visit). (NCT01905943)
Timeframe: 3 months after the last dose of study treatment (up to approximately 5 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Blood | Bone Marrow | |
| G Mono: Previously Untreated Fit | 8.3 | 4.2 |
| G Mono: Previously Untreated Unfit | 23.1 | 3.8 |
| G Mono: Relapsed/Refractory | 4.1 | 2.0 |
| G-Benda: Previously Untreated Fit | 63.1 | 31.5 |
| G-Benda: Previously Untreated Unfit | 65.3 | 27.2 |
| G-Benda: Relapsed/Refractory | 39.8 | 14.9 |
| G-Clb: Previously Untreated Unfit | 9.4 | 5.7 |
| G-Clb: Relapsed/Refractory | 6.3 | 3.1 |
| G-FC: Previously Untreated Fit | 72.0 | 40.0 |
| G-FC: Previously Untreated Unfit | 58.3 | 41.7 |
| G-FC: Relapsed/Refractory | 51.5 | 24.2 |
17 reviews available for chlorambucil and Recrudescence
| Article | Year |
|---|---|
Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Topics: Adolescent; Alkylating Agents; Azathioprine; Child; Child, Preschool; Chlorambucil; Cyclophosphamide | 2020 |
Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Cyclosporine; Dru | 2019 |
Primary bone marrow lymphoma is a rare neoplasm with poor outcome: case series from single tertiary care centre and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biopsy; Bone Marrow; Bone Marrow Exam | 2016 |
Chronic lymphocytic leukemia: something old, something new and something borrowed...
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benda | 2011 |
Hairy cell leukemia and variant in Taiwan: report of a variant case and literature review.
Topics: Acid Phosphatase; Aged; Antigens, CD; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Mar | 2011 |
[Waldenstrom macroglobulinemia].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, M | 2004 |
Use of rituximab in patients with follicular lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2007 |
[Treatment of nephrotic syndrome in children (author's transl)].
Topics: Adrenal Cortex Hormones; Child; Chlorambucil; Cyclophosphamide; Humans; Nephrotic Syndrome; Recurren | 1980 |
Nephrotic syndrome in childhood. Management and treatment in patients with minimal change disease, mesangial proliferation, or focal glomerulosclerosis.
Topics: Adolescent; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Diuretics; Female; Glomerulonep | 1982 |
Nephrotic syndrome in childhood. Management and treatment in patients with minimal change disease, mesangial proliferation, or focal glomerulosclerosis.
Topics: Adolescent; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Diuretics; Female; Glomerulonep | 1982 |
Nephrotic syndrome in childhood. Management and treatment in patients with minimal change disease, mesangial proliferation, or focal glomerulosclerosis.
Topics: Adolescent; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Diuretics; Female; Glomerulonep | 1982 |
Nephrotic syndrome in childhood. Management and treatment in patients with minimal change disease, mesangial proliferation, or focal glomerulosclerosis.
Topics: Adolescent; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Diuretics; Female; Glomerulonep | 1982 |
Immunosuppressive agents in childhood nephrotic syndrome: a meta-analysis of randomized controlled trials.
Topics: Adolescent; Adrenal Cortex Hormones; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Cyclos | 2001 |
A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children.
Topics: Antineoplastic Agents, Alkylating; Child; Chlorambucil; Cyclophosphamide; Humans; Nephrotic Syndrome | 2001 |
Non-corticosteroid treatment for nephrotic syndrome in children.
Topics: Adolescent; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Humans; Immunosuppressive Agent | 2001 |
Conventional therapy for idiopathic nephrotic syndrome in children.
Topics: Child; Chlorambucil; Cyclophosphamide; Humans; Nephrosis, Lipoid; Prednisone; Recurrence | 1991 |
The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies.
Topics: Alkylating Agents; Child; Chlorambucil; Cyclophosphamide; Cyclosporins; Humans; Immunosuppressive Ag | 1991 |
[Therapy of lupus-nephritis using corticosteroids and immunosuppressive agents].
Topics: Adrenal Cortex Hormones; Antibodies, Antinuclear; Azathioprine; Beta-Globulins; Chlorambucil; Cyclop | 1974 |
[Prognosis of the idiopathic nephrotic syndrome in children].
Topics: Adrenocorticotropic Hormone; Biopsy; Blood Proteins; Chlorambucil; Cyclophosphamide; Female; Humans; | 1974 |
Immunosuppressant agents in the treatment of glomerulonephritis. 2. Cytotoxic drugs.
Topics: Adult; Anti-Glomerular Basement Membrane Disease; Antilymphocyte Serum; Antineoplastic Agents; Azath | 1971 |
20 trials available for chlorambucil and Recrudescence
| Article | Year |
|---|---|
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi | 2021 |
A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Diseas | 2006 |
Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chlorambucil; C | 2007 |
Mitoxantrone, teniposide, chlorambucil and prednisone (MVLP) for relapsed non-Hodgkin's lymphoma. The impact of advanced age and performance status.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophospha | 1993 |
High-dose chlorambucil and dexamethasone for relapsed non-Hodgkin's lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dexame | 1993 |
A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.
Topics: Adult; Aged; Chlorambucil; Creatinine; Female; Follow-Up Studies; Glomerulonephritis, Membranous; Hu | 1995 |
A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.
Topics: Adult; Aged; Chlorambucil; Creatinine; Female; Follow-Up Studies; Glomerulonephritis, Membranous; Hu | 1995 |
A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.
Topics: Adult; Aged; Chlorambucil; Creatinine; Female; Follow-Up Studies; Glomerulonephritis, Membranous; Hu | 1995 |
A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.
Topics: Adult; Aged; Chlorambucil; Creatinine; Female; Follow-Up Studies; Glomerulonephritis, Membranous; Hu | 1995 |
Treatment of refractory low grade lymphoma with chlorambucil alternating with interferon and radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Moda | 1995 |
The follicular non-Hodgkin's lymphomas--I. The possibility of cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Cyclophosph | 1996 |
A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.
Topics: Adolescent; Adult; Aged; Amenorrhea; Anemia; Antineoplastic Agents, Alkylating; Carcinoma; Chlorambu | 1998 |
A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.
Topics: Adolescent; Adult; Aged; Amenorrhea; Anemia; Antineoplastic Agents, Alkylating; Carcinoma; Chlorambu | 1998 |
A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.
Topics: Adolescent; Adult; Aged; Amenorrhea; Anemia; Antineoplastic Agents, Alkylating; Carcinoma; Chlorambu | 1998 |
A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.
Topics: Adolescent; Adult; Aged; Amenorrhea; Anemia; Antineoplastic Agents, Alkylating; Carcinoma; Chlorambu | 1998 |
Long-term effects of immunosuppressants in steroid-dependent nephrotic syndrome.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Child; Child, Preschool; Chlorambucil; Cyclophosphamide | 1998 |
Short-term chlorambucil for refractory uveitis in Behcet's disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Behcet Syndrome; Child; Chlorambucil; Female; | 2001 |
Controlled trial of chlorambucil in frequently relapsing nephrotic syndrome in children (a preliminary report).
Topics: Child; Child, Preschool; Chlorambucil; Clinical Trials as Topic; Double-Blind Method; Female; Humans | 1978 |
[Use of leukeran in the overall therapy of chronic glomerulonephritis in children].
Topics: Adolescent; Child; Child, Preschool; Chlorambucil; Chronic Disease; Clinical Trials as Topic; Drug E | 1977 |
Adjuvant chemotherapy in breast cancer--Swiss co-operative studies.
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Drug T | 1979 |
Chlorambucil dosage in frequently relapsing nephrotic syndrome: a controlled clinical trial.
Topics: Adolescent; Child; Child, Preschool; Chlorambucil; Humans; Nephrotic Syndrome; Recurrence; Remission | 1978 |
[Results of immunosuppressive therapy in 78 patients with rheumatoid polyarthritis, treated for at least 4 years].
Topics: Adrenal Cortex Hormones; Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Chlorambucil; Clin | 1975 |
Chlorambucil treatment of frequently relapsing nephrotic syndrome.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Chlorambucil; Drug Evaluation; Drug Therapy, Combi | 1976 |
Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology.
Topics: Adolescent; Child; Child, Preschool; Chlorambucil; Creatinine; Cyclosporine; Drug Administration Sch | 1992 |
The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies.
Topics: Alkylating Agents; Child; Chlorambucil; Cyclophosphamide; Cyclosporins; Humans; Immunosuppressive Ag | 1991 |
Interferon-alpha 2b in the treatment of follicular lymphoma: preliminary results of a trial in progress.
Topics: Adult; Aged; Aged, 80 and over; Chlorambucil; Drug Administration Schedule; Female; Follow-Up Studie | 1991 |
61 other studies available for chlorambucil and Recrudescence
| Article | Year |
|---|---|
Orbitary MALT lymphoma in a patient diagnosed with non-Hodgkin lymphoma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; H | 2015 |
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Chlorambuc | 2014 |
[Efficacy Analysis of MAC Regimen as Salvage Treatment Protocol for Acute Myeloid Leukemia Patients Older Than 55 Years].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cytarabine; Dactinomycin; Humans; Leuk | 2015 |
Recurrent penile ulcer as a manifestation of chronic lymphocytic leukaemia.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Diagnosis, Differen | 2008 |
Evaluation of certain constituents of antioxidant defense in youth treated in the past for steroid-sensitive idiopathic nephrotic syndrome.
Topics: Adolescent; Anthropometry; Antioxidants; Aryldialkylphosphatase; Ascorbic Acid; Case-Control Studies | 2009 |
Chemotherapy-related magnetic resonance imaging abnormalities mimicking disease progression following intraventricular liposomal cytarabine and high dose methotrexate for neurolymphomatosis.
Topics: Aged; Antineoplastic Agents; Autopsy; Brain; Brain Injuries; Chlorambucil; Cytarabine; Disease Progr | 2012 |
[Therapeutic regimen in Vogt-Koyanagi-Harada syndrome].
Topics: Adolescent; Adult; Child; Chlorambucil; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Me | 2002 |
[Relapsing nephrotic syndrome in a diabetic patient with minimal change].
Topics: Chlorambucil; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diagnosis, Differential; Drug Thera | 2004 |
Extranodal mantle cell lymphoma in a prolapsed ileostomy stump.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dexamethasone; Humans; Ileal Neo | 2005 |
Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Agents, Alkylating; Child, Preschool; Chlorambucil; C | 2005 |
[Recent advances in therapy for nephrotic syndrome in children].
Topics: Anti-Inflammatory Agents; Azathioprine; Child; Chlorambucil; Cyclophosphamide; Drug Administration S | 2007 |
[Leukaemia cutis: clinical manifestation of chronic lymphocytic leukaemia relapse].
Topics: Aged; Antineoplastic Agents, Alkylating; Biopsy; Chlorambucil; Humans; Leukemia, Lymphocytic, Chroni | 2007 |
[Effect of mechlorethamine in idiopathic nephrotic syndrome in childhood].
Topics: Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Drug Tolerance; Female; Glomerulosclerosis, | 1984 |
Steroid-dependent nephrotic syndrome in lupus nephritis. Response to chlorambucil.
Topics: Adult; Chlorambucil; Female; Glomerulonephritis; Humans; Lupus Erythematosus, Systemic; Nephrotic Sy | 1984 |
Treatment of nephrotic syndrome with levamisole.
Topics: Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Female; Follow-Up Studies; Humans; Levamiso | 1980 |
Treatment of the idiopathic nephrotic syndrome.
Topics: Alkylating Agents; Child; Chlorambucil; Cyclophosphamide; Drug Resistance; Glomerulonephritis; Human | 1981 |
Immune deposits and mesangial hypercellularity in minimal change nephrotic syndrome: clinical relevance.
Topics: Adolescent; Biopsy; Child; Child, Preschool; Chlorambucil; Complement C3; Complement C4; Cyclophosph | 1982 |
Multiple relapsing steroid responsive nephrosis treated with chlorambucil.
Topics: Adult; Chlorambucil; Drug Therapy, Combination; Humans; Male; Nephrotic Syndrome; Prednisone; Recurr | 1982 |
Chlorambucil for childhood nephrosis: a word of caution.
Topics: Adrenal Cortex Hormones; Child; Chlorambucil; Humans; Nephrotic Syndrome; Recurrence | 1980 |
Cytotoxic treatment in children with idiopathic nephrotic syndrome.
Topics: Adolescent; Antineoplastic Agents; Child; Chlorambucil; Cyclophosphamide; Follow-Up Studies; Humans; | 1980 |
[T-cell lymphoma under immunosuppressive treatment in minimal change glomerulopathy with nephrotic syndrome].
Topics: Adult; Chlorambucil; Cyclosporins; Female; Humans; Immunosuppressive Agents; Lymphoma, T-Cell; Nephr | 1995 |
Alternative treatment to corticosteroids in steroid sensitive idiopathic nephrotic syndrome.
Topics: Adrenal Cortex Hormones; Child; Child, Preschool; Chlorambucil; Chloramphenicol; Cyclophosphamide; C | 1994 |
Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance.
Topics: 2-Chloroadenosine; Aged; Chlorambucil; Drug Resistance; Erythrocyte Transfusion; Female; Follow-Up S | 1994 |
Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; H | 1994 |
In what order should one introduce cyclophosphamide or chlorambucil, cyclosporine or levamisole in a child with steroid-dependent frequently relapsing nephrotic syndrome?
Topics: Child; Chlorambucil; Cyclophosphamide; Cyclosporine; Drug Administration Schedule; Glucocorticoids; | 1993 |
A case of refractory adult dermatomyositis.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Creatine Kinase; D | 1998 |
The patient with over 100 relapses of minimal change nephrotic syndrome: prolonged complete remission after chlorambucil treatment.
Topics: Adult; Blood Pressure; Chlorambucil; Disease-Free Survival; Humans; Male; Nephrotic Syndrome; Recurr | 2000 |
Drug-induced acute malaria.
Topics: Acute Disease; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Female; Hu | 2000 |
Treatment of Behçet's disease--an update.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Behcet Syndrome; Chl | 2001 |
Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia?
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2001 |
Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome.
Topics: Adolescent; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Cyclosporine; Drug Therapy, Com | 2001 |
High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents, Alkylating; Ch | 2002 |
Adjuvant chemo-immuno-therapy with LMF+BCG in node-negeative and node-positive breast cancer.
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Chlorambucil; Drug Therapy, Combination; Femal | 1978 |
[Clinical course and recurrences of the nephrotic syndrome due to minimal histologic lesions. Review of 73 cases (author's transl)].
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Chlorambucil; Drug Therapy, Combination; Fe | 1979 |
The treatment of advanced and recurrent Hodgkin's disease with chlorambucil, vinblastine, procarbazine and prednisone in combination.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Child; Chlorambucil; Drug Therapy, Comb | 1979 |
Immunoblastic lymphadenopathy. Patient with prolonged fever of unknown origin.
Topics: Adult; Chlorambucil; Female; Fever of Unknown Origin; Humans; Immunoblastic Lymphadenopathy; Lymph N | 1979 |
[Experiences with cytotoxic drugs in therapy of the nephrotic syndrome].
Topics: Adolescent; Adult; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Glomerulonephritis; Huma | 1977 |
Treatment of Behcet disease with chlorambucil. A follow-up report.
Topics: Adult; Behcet Syndrome; Chlorambucil; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; M | 1976 |
How to manage a child with steroid-responsive nephrotic syndrome when dose of prednisolone is reduced or when placed on high-dose alternate day steroids.
Topics: Child, Preschool; Chlorambucil; Cyclophosphamide; Female; Humans; Nephrotic Syndrome; Prednisolone; | 1992 |
CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemothera | 1991 |
The use of chlorambucil in the treatment of bullous pemphigoid.
Topics: Age Factors; Aged; Aged, 80 and over; Chlorambucil; Drug Administration Schedule; Drug Therapy, Comb | 1990 |
The 'urn' portal; an alternative to the 'mantle' portal in the chemoradiotherapy management of paediatric Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chlorambucil; C | 1990 |
The use of pulse methylprednisolone and chlorambucil in the treatment of Sweet's syndrome.
Topics: Biopsy; Chlorambucil; Chronic Disease; Dermatitis; Female; Fever; Humans; Methylprednisolone; Middle | 1989 |
Linear growth of children with nephrotic syndrome: effect of alkylating agents.
Topics: Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Female; Growth; Humans; Infant; Kidney; Mal | 1989 |
Remission induced by chlorambucil in steroid-responsive, frequently relapsing nephrotic syndrome that relapsed after cyclophosphamide.
Topics: Administration, Oral; Child; Chlorambucil; Cyclophosphamide; Drug Administration Schedule; Drug Eval | 1989 |
Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Chlorambucil; Female; Hodg | 1989 |
Functional properties in Sézary cells with an unusual phenotype.
Topics: Aged; Antibodies, Monoclonal; Chlorambucil; Dermatitis, Exfoliative; Drug Therapy, Combination; Huma | 1985 |
Relapsing nephrotic syndrome.
Topics: Captopril; Chlorambucil; Cyclophosphamide; Cyclosporins; Glomerular Mesangium; Humans; Immune Comple | 1987 |
Beneficial effect of second courses of cytotoxic therapy in children with minimal change nephrotic syndrome.
Topics: Adolescent; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Drug Resistance; Female; Humans | 1988 |
[Therapeutic results in recurrent breast cancer with the use of Bestrabucil (KM2210)].
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Drug Evaluation; Estradiol; Female; Hu | 1987 |
Nephrotic syndrome in two patients with cured Hodgkin's disease.
Topics: Adult; Chlorambucil; Gallium Radioisotopes; Hodgkin Disease; Humans; Male; Nephrosis, Lipoid; Nephro | 1985 |
Chlorambucil in steroid-dependent nephrotic syndrome.
Topics: Adolescent; Beta-Globulins; Blood Pressure; Child; Child, Preschool; Chlorambucil; Drug Synergism; F | 1973 |
Prognosis and survival with extranodal Hodgkin's disease.
Topics: Adult; Carmustine; Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Human | 1974 |
The use of chlorambucil in intractable idiopathic uveitis.
Topics: Adolescent; Arthritis, Rheumatoid; Behcet Syndrome; Blood Cell Count; Blood Platelets; Chemical Phen | 1974 |
[Chemotherapy of lymphogranulomatosis].
Topics: Adolescent; Age Factors; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Drug Combinations; D | 1974 |
A clinical study of the natural history of lymphosarcoma and reticulum cell sarcoma.
Topics: Adult; Aged; Chlorambucil; Cyclophosphamide; Female; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Mal | 1974 |
Experience with a new technique for "total node" irradiation--Hodgkin's disease.
Topics: Adolescent; Adult; Biopsy; Blood Cells; Child; Chlorambucil; Female; Hodgkin Disease; Humans; Liver | 1974 |
The idiopathic nephrotic syndrome of childhood. A clinical reevaluation of 148 cases.
Topics: Adolescent; Antistreptolysin; Azathioprine; Bacteriuria; Blood Urea Nitrogen; Child; Child, Preschoo | 1974 |
Long-term follow-up of cyclophosphamide therapy in frequent relapsing minimal lesion nephrotic syndrome.
Topics: Adolescent; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Drug Resistance; Follow-Up Stud | 1974 |
[Use of vinblastine and leukeran in lymphogranulomatosis].
Topics: Adolescent; Adult; Chlorambucil; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Ag | 1972 |
[Experiences in the treatment of dermatomyositis with immunosuppressiva].
Topics: Azathioprine; Child; Child, Preschool; Chlorambucil; Dermatomyositis; Drug Resistance; Drug Toleranc | 1972 |